Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Somalia: Majority Of North Mogadishu Population Flees As Fighting Escalates
The resumption of fighting in Mogadishu, Somalia"s capital, has forced the majority of people living in the Yaqshid, Karan, and Abdul Azziz districts in the north of the city to flee, according to the international medical humanitarian organization Doctors Without Borders/Mç©decins Sans Frontiç¨res (MSF). Continuous shelling, explosions, and open combat among various armed groups have claimed the lives of dozens of civilians and plunged the city into chaos. As a consequence, MSF has been forced to close its medical centers in the area.
pharmacy online
Foresight Biotherapeutics Announces FST-100 Displays Robust Clinical Improvement In Adenoviral Conjunctivitis Model
Foresight Biotherapeutics, Inc. announced data from a pre-clinical study designed to assess the safety and efficacy of the topical administration of FST-100 in a highly regarded Ad5 NZW rabbit model of adenoviral conjunctivitis. FST-100 demonstrated a clinically and statistically significant reduction in signs of adenoviral conjunctivitis versus all other groups including the current experimental "gold standard", topical cidofovir. The study was conducted at the Louisiana State University (LSU) Health Science Center, LSU Eye Center in New Orleans, Louisiana by Professor James M. Hill and colleagues, in the Departments of Pharmacology, Microbiology, Ophthalmology and Neuroscience.
News of the day
White House Reform Chief Was On Boards Of Health Companies With Suspect Practices
Before taking her job as the White House health reform director, Nancy-Ann DeParle earned more than $6 million serving on the boards of major health care corporations, some of which were accused of fraud, mismanagement and regulatory violations during her tenure, the Investigative Reporting Workshop at American University reports on MSNBC.com. Some critics say the corporate relationships could be a conflict of interest for DeParle. Also, while there"s no evidence DeParle was involved in or aware of allegedly fraudulent activities, in three cases, she served on board committees overseeing the companies" legal and regulatory compliance.
Public Health

Medivation Selects ProTrials To Conduct International Phase III Clinical Trials

ProTrials Research, Inc.TM, a leader in the clinical research organization industry, announced Medivation, Inc. (NASDAQ:MDVN) has chosen the company to conduct separate international Phase III clinical trials for two novel treatments. ProTrials will test MDV3100 for treating prostate cancer and the investigational drug Dimebon TM as a treatment for Huntington"s disease. Due to the complex nature of these Phase III trials, Medivation again selected ProTrials as its contract research organization partner because of ProTrials" successful past performance with the company"s Phase I, II and III trials. "We are working with ProTrials specifically because of its people and their long track records of conducting clinical trials," noted Lynn Seely, M.D., chief medical officer at Medivation. "While many CROs have research managers that are industry veterans, it"s unusual to find a CRO offering such deep experience levels across the team." ProTrials will oversee the Huntington"s trial across the United States, Canada and Europe, and the United States and Canada for the prostate cancer trial. Both clinical trials are expansive in nature, involving hundreds of patients and about 125 test sites total. They will both be randomized and placebo-controlled. "Medivation"s repeated selection of ProTrials as a clinical trials partner is a nod to our track record of efficiency, cost effectiveness and most importantly, our GCP compliance in conducting clinical trials," said ProTrials CEO Jodi Andrews. "With prostate cancer being one of the most prevalent types of cancer in men, and Huntington"s disease having no treatments currently approved by the U.S. Food and Drug Administration, these Phase III clinical trials are crucial for moving potentially life-saving treatments to market." Visitors to the upcoming 2009 American Society for Clinical Oncology (ASCO), being held May 29-June 2 at the Orange County Convention Center in Orlando, FL, can learn more about ProTrials in booth #703. ProTrials will also be attending the 45th Annual Meeting of the Drug Information Association (DIA), being held June 21-25 at the San Diego (CA) Convention Center, and will be in booth #1215. ProTrials Research, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009